We are delighted to team up with Clinical Laserthermia Systems Americas this week for a groundbreaking episode where we dive into the world of cutting-edge medical technology and shed light on an emerging innovation that promises to revolutionize the management of prostate cancer!
CLS is a leading medical device company at the forefront of pioneering precise and effective interventional healthcare solutions. They have developed an innovative CLS thermal therapy system for image-guided focal laser ablation that spares healthy tissue while minimizing the debilitating side effects often associated with traditional treatments. This technology can even be administered by a urologist in an office setting, bringing hope and convenience to countless patients.
We are honored to have Michael Magnani, the President of CLS, joining us today to explore their new thermal therapy system for image-guided focal laser ablation. With a career spanning over two decades in corporate management within the life sciences industry, he brings a wealth of expertise in product development, corporate strategy, business development, and commercialization. He graduated from the unique Biomedical Enterprise Program at the MIT Sloan School of Management and holds a Bachelor of Science in Microbiology from the University of California, San Diego.
Join us to learn about the exciting possibilities this transformative new technology holds for the future of prostate cancer management!
Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation.
Show highlights:
- Michael discusses what they are doing at CLS
- The benefits of offering targeted focal therapy as an alternative treatment for prostate cancer
- Michael walks through the device components of the CLS thermal therapy system, explaining how it works in targeting prostate cancer and how it gets deployed within a urological setting
- What are the advantages of using targeted focal laser ablation for prostate cancer?
- Who would be considered an appropriate candidate for CLS thermal therapy?
- Some of the potential risks associated with focal laser ablation treatment
- How the CLS mobile services model works for a urologist practice
- How can adopting a concierge business model allow urologists to provide early access to some emerging technologies?
- What can a patient expect during the procedure and in the recovery phase?
The strides made by CLS in developing its CLS thermal therapy system for image-guided focal laser ablation offers hope for countless patients. The future of prostate cancer management is undoubtedly brighter with innovations like these, and we invite you to tune into future episodes where we will continue to explore the new and transformative possibilities that lie ahead.
Thank you for joining us on this remarkable journey of discovery!
Links:
Follow Dr. Pohlman on Twitter and Instagram – @gpohlmanmd
Get your free What To Expect Guide (or find the link on our podcast website)
Join our Facebook group
Follow Dr. Pohlman on Twitter and Instagram
Go to the Prostate Health Academy to sign up.
You can access Dr. Pohlman’s free mini webinar, where he discusses his top three tips to promote men’s prostate health, longevity, and quality of life here.
Recent Comments